[AACR 2026] From CXCR4 to GPRC5D: Which GPCR Targets Are Gaining Momentum in Oncology
6. CCR5: Repositioning a Classic GPCR Target in Oncology
Unlike newer GPCR targets, CCR5 is a well-established target in inflammation and infectious diseases. However, AACR 2026 highlights its renewed potential in oncology.
Key developments include: repurposing of leronlimab and maraviroc, combination strategies with chemotherapy, anti-angiogenic agents, and immunotherapy, and roles in tumor microenvironment regulation and metastasis.
This represents a classic case of “old target, new applications”, with strong translational potential. Representative abstracts include:
(I can't copy & paste the abstract titles but you can see them here)...
https://www.dimabio.com/blog/popular-gpcr-tar...-aacr-2026